Precigen, Inc. (PGEN) is an innovative biopharmaceutical company that builds a robust portfolio of groundbreaking gene and cell therapies to address unmet medical needs. Headquartered in Germantown, Maryland, Precigen, a subsidiary of Intrexon Corporation, aims to revolutionize health care by developing practical, advanced gene and cell therapies using next-generation precision technology.
The company concentrates on developing gene therapies for critical illnesses in several therapeutic areas, including immunology, oncology, and rare diseases. Precigen specializes in using revolutionary synthetic biology techniques to design and develop innovative therapeutic solutions. Precigen functions by operating via its compelling proprietary UltraCAR-T platform, which leverages non-viral gene delivery technology to genetically reprogram patients’ T cells into highly potent, targeted cancer therapies manufactured in less than two days.
Precigen Inc. is committed to transforming the field of cell and gene therapy, with an emphasis on curative and therapeutic solutions. Their work includes developing new treatments for cancer and other serious diseases that currently lack effective therapies. They are also researching potential therapies for autoimmune diseases and infectious diseases, among other areas.
PREGEN's promising pipeline includes PRGN-3005 UltraCAR-T, a treatment for ovarian cancer that is currently in the early stages of clinical trials, and PRGN-3006 UltraCAR-T, a potential treatment for acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS), also in early-stage clinical trials.
The company operates under the philosophy of taking a patient-first approach and is passionately committed to advancing science and technology to enhance the quality of life for patients and their families around the world.
Precigen is listed under the symbol PGEN on the NASDAQ stock exchange. The company's recent deal to monetize certain assets and streamline its focus on healthcare opened new financing options for the firm. This deal also allowed Precigen to put more resources into advancing its clinical-stage therapies, which could eventually lead to significant advances in the world of medicine.
From a financial perspective, Precigen has a significant war chest at its disposal for developing and testing its therapies. As of the last report, Precigen had over $120 million in cash and cash equivalents, which should allow it to continue its research and development unabated.
In summary, Precigen, Inc. is an innovative and exciting company that is pushing the boundaries of what's possible in gene and cell therapy. With a patient-centric approach, major achievements on the horizon, and promising clinical trials underway, Precigen is a company to watch in the world of biotechnology.